drugset / Trial / NCT03296306

Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma

NCT03296306

RandomizedParallel-groupOpen-labelTreatment

Summary

The objective is to show non-inferiority of overall survival between four cycles and six cycles of first-line cisplatin based chemotherapy to determine the optimal duration of chemotherapy in patients with advanced urothelial carcinoma.

Timeline

Start
2016-09
Primary completion
2021-08
Completion
2022-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 35 mg/m2
Subject Cisplatin Other / unclassified 60 mg/m2
Subject Cisplatin Other / unclassified 70 mg/m2
Subject Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2
Subject Methotrexate Small molecule 30 mg/m2 Intravenous
Subject Vinblastine Small molecule 3 mg/m2 Intravenous